MDL 3140 Update: Where the Depo-Provera Litigation Stands in April 2026

MDL 3140 is the federal litigation hub for Depo-Provera meningioma cases. Established in late 2024, the multidistrict litigation now has well over 1,700 active plaintiffs and is entering its most consequential phase: bellwether trial selection. Here's where things stand as of April 2026, and what it means for women who've filed or are considering filing.

What Is MDL 3140?

A multidistrict litigation (MDL) is a procedural mechanism in the federal court system designed to handle large-scale product liability cases efficiently. When hundreds or thousands of plaintiffs across different states file similar lawsuits against the same defendant, the Judicial Panel on Multidistrict Litigation (JPML) can consolidate those cases in a single district for coordinated pretrial proceedings.

MDL 3140, formally titled "In Re: Depo-Provera (Medroxyprogesterone Acetate) Products Liability Litigation," was established by the JPML and assigned to the Northern District of Illinois, where it is presided over by U.S. District Judge John Z. Lee.

Consolidation doesn't mean all cases will be tried together. Each plaintiff still has an individual claim. But it allows the parties to conduct coordinated discovery, share expert witnesses, and resolve common legal and factual questions without duplicating that work in hundreds of individual courts.

Current Case Count: More Than 1,700 and Growing

As of early April 2026, MDL 3140 has over 1,700 active cases. That figure has climbed steadily since the FDA issued its black box warning in August 2024, which served as a public notification event driving many women to consult attorneys for the first time.

Mass tort attorneys tracking the litigation project the final case count could reach 5,000 or more by the time all eligible plaintiffs file. Several factors are driving continued growth:

• The 2024 FDA warning created a widely publicized connection between Depo-Provera and brain tumors, reaching women who had never previously considered the drug's long-term risks
• Statute of limitations periods in many states run from the date of FDA disclosure, not the date of diagnosis, giving women who were diagnosed years ago a new filing window
• Ongoing media coverage of the MDL is prompting self-referrals from women who used the drug in the 1990s and 2000s
• Some states have two-year windows; others allow up to three years from discovery, creating rolling filing deadlines through 2026 and 2027

The Bellwether Selection Process

Bellwether trials are the pressure test of mass tort litigation. The parties, under the court's direction, select a small subset of cases — typically 10 to 20 — that are meant to represent the broader plaintiff pool. These cases go to trial first, and the verdicts serve as data points for settlement negotiations on the remaining cases.

Bellwether selection in MDL 3140 began in earnest in early 2026. The process involves several steps:

Plaintiff pool creation. All plaintiffs must complete Plaintiff Fact Sheets (PFS), detailed questionnaires documenting their Depo-Provera use history, medical records, diagnoses, and claimed damages. The PFS data is being used to sort plaintiffs into subgroups based on use duration, formulation, and injury type.

Case selection. Plaintiffs' Steering Committee (PSC) and defendants' counsel each identify candidate cases. Judge Lee's chambers apply criteria to find cases that are factually representative, legally clean (no unusual complicating factors), and appropriately diverse geographically and demographically.

Discovery. Selected bellwether cases go through full fact discovery and expert discovery. Plaintiffs' experts will testify on the MPA-meningioma causation science; defendants' experts will contest the epidemiology. Key depositions of Pfizer scientists and regulatory affairs personnel will occur during this phase.

The first bellwether trials in MDL 3140 are anticipated for late 2026 at the earliest, with 2027 being a realistic target if discovery proceeds on schedule.

Who Is Being Sued

The primary defendant in MDL 3140 is Pharmacia & Upjohn Company LLC, a wholly owned subsidiary of Pfizer Inc. Pharmacia manufactured and marketed Depo-Provera for decades and holds the NDA (New Drug Application) for the product.

Pfizer acquired Pharmacia in 2003 and has continued manufacturing and selling Depo-Provera under the same brand. Some plaintiffs also name Greenstone LLC, another Pfizer subsidiary that produces the generic medroxyprogesterone acetate injectable. Cases involving the generic formulation raise additional legal complexity around the FDA preemption doctrine — a doctrine that may provide different defenses for generic manufacturers versus brand-name companies.

The core legal theories asserted by plaintiffs include: failure to warn (the label didn't disclose the meningioma risk despite available evidence), negligent design, and in some cases fraud-on-the-regulatory-agency (a harder claim to win).

Settlement Signals: What to Watch For

No global settlement has been announced as of April 2026. That's not unusual for an MDL at this stage. In large pharmaceutical mass torts, defendants rarely negotiate in earnest until:

1. Discovery is substantially complete and defendants know the strength of the evidence against them
2. One or more bellwether trials have produced verdicts, giving both sides real data on jury behavior
3. The case count is large enough that global resolution is financially efficient for the defendant

By these metrics, MDL 3140 is probably 18 to 24 months from serious settlement talks. For reference, the Essure MDL (In Re: Essure Products Liability Litigation, MDL 2769) took about four years from consolidation to a global settlement. The NuvaRing MDL settled in about five years. Depo-Provera is on a similar timeline, though the volume of cases could accelerate negotiations.

One early settlement signal to watch: if Pfizer settles any bellwether cases before trial (which defendants sometimes do to remove particularly strong plaintiff cases from the jury pool), that indicates they're aware of liability exposure and managing it case-by-case before committing to a global number.

What to Expect Next

Spring 2026: Bellwether pool finalized. Plaintiff Fact Sheets reviewed, candidate cases selected.

Summer 2026: Fact discovery in bellwether cases. Depositions of Pfizer witnesses and plaintiffs' medical experts.

Fall 2026 to Winter 2026-27: Expert discovery, Daubert motions (challenges to expert testimony). This phase determines what science the jury actually hears.

2027: First bellwether trial(s). Verdicts signal settlement range.

2027-2028: If verdicts favor plaintiffs, expect global settlement negotiations to begin in earnest.

This timeline can accelerate or slow depending on Pfizer's litigation strategy, the pace of discovery disputes, and any unexpected developments in the science.

For background on the underlying science driving this litigation, see our pieces on the FDA's 2024 black box warning and the meningioma latency period research. Our full MDL 3140 reference page provides ongoing updates as case law develops.

Related Resources

• MDL 3140 Reference Hub
• How to File a Depo-Provera Claim
• Understanding Settlement Ranges
• FDA 2024 Black Box Warning Explained
• Meningioma Development Timeline

Frequently Asked Questions